Semaglutide, 1.0 mg/mL

DRUG5 trials

Sponsors

Novo Nordisk A/S, Vivani Medical, Inc, University Health Network, Toronto, Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA), Attikon Hospital

Conditions

Diabetes Mellitus, Type 2Diabetes Type 2Kidney Transplant RecipientsOverweight and ObesityType2diabetes

Phase 1

A Research Study to Look at Similarity Between Semaglutide Versions in Different Injection Tools

CompletedNCT03598621

Novo Nordisk A/SDiabetes Mellitus, Type 2

Start: 2018-07-23End: 2019-01-17Updated: 2020-01-09

Assessment of Safety, Tolerability and Drug Levels of Exenatide Implant

CompletedNCT05670379

Vivani Medical, IncOverweight and Obesity, Type2diabetes

Start: 2024-12-20End: 2025-08-21Updated: 2025-09-23

Phase 2

The Efficacy, Mechanism & Safety of Sodium Glucose Co-Transporter-2 Inhibitor & Glucagon-Like Peptide 1 Receptor Agonist Combination Therapy in Kidney Transplant Recipients

RecruitingNCT05938712

University Health Network, TorontoKidney Transplant Recipients

Start: 2023-10-24End: 2025-10-01Target: 20Updated: 2025-01-31

Unknown Phase

A Trial to Evaluate Safety, Feasibility and Efficacy of the ReCET Procedure (EMINENT-2)

Active, not recruitingNCT05984238

Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)Diabetes Mellitus, Type 2

Start: 2023-08-03End: 2026-07-31Target: 32Updated: 2026-01-15

The Effect of Semaglutide on Cardiovascular Markers and Liver Function

RecruitingNCT06301191

Attikon HospitalDiabetes Type 2

Start: 2022-03-01End: 2024-05-01Target: 50Updated: 2024-03-08

Related Papers

Optimizing duodenal tissue acquisition for mechanistic studies of duodenal ablation in type 2 diabetes

Endoscopy International Open2024-12-16